FDA Authorizes New Class of ADHD Medication for Pediatric and Adult Patients

The U.S. FDA has approved Simtriyo (centanafadine), an extended-release capsule, for treating ADHD in adults and children aged 6 and older. This marks the first FDA-approved norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) for ADHD, introducing a new treatment class with a distinct mechanism of action. This approval provides a novel therapeutic option for individuals managing ADHD.